CoChat
Sign Up
Cited by 149Viral Infections and Immunology ResearchImmune responses and vaccinationsT-cell and B-cell Immunology

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus.

Open access
Herremans, Tineke M P T, Reimerink, Johan H J, Buisman, Annemarie M, Kimman, Tjeerd G, Koopmans, Marion P G·1999·The Journal of Immunology
DOI 10.4049/jimmunol.162.8.5011
Open this paper in CoChat — free accountOpen PDF

Abstract

The inactivated poliovirus vaccine (IPV) is used for protection against poliomyelitis in The Netherlands. It is not clear, however, whether IPV vaccination can lead to priming of the mucosal immune system and the induction of IgA. It has been demonstrated that IPV vaccination is able to induce strong memory IgA responses in the serum of persons who have been naturally exposed to wild-type poliovirus. This has led to the hypothesis that IPV vaccination is able to induce poliovirus-specific IgA at mucosal sites in persons who have been previously primed with live poliovirus at mucosal sites. To test this hypothesis, the kinetics of the IgA response in serum and saliva after IPV vaccination were examined in persons previously vaccinated with oral poliovirus vaccine (OPV) or IPV. ELISA and enzyme-linked immunospot assays were used for the detection of poliovirus-specific IgA responses. In addition, B cell populations were separated on the basis of the expression of mucosal (α4β7 integrin) and peripheral homing receptors (L-selectin). Parenteral IPV vaccination was able to boost systemic and mucosal IgA responses in previously OPV-vaccinated persons only. None of the previously vaccinated IPV recipients responded with the production of IgA in saliva. In agreement with this finding, a large percentage of the poliovirus-specific IgA-producing lymphocytes detected in previous OPV recipients expressed the α4β7 integrin. It is concluded that IPV vaccination alone is insufficient to induce a mucosal IgA response against poliovirus. In mucosally (OPV-) primed individuals, however, booster vaccination with IPV leads to a strong mucosal IgA response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.162.8.5011

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The impact of IPV in these studies is perhaps more likely to relate to local immunity induced by IPV through transudation of serum IgG rather than induction of a local secretory IgA response.

    “The impact of IPV in these studies is perhaps more likely to relate to local immunity induced by IPV through transudation of serum IgG rather than induction of a local secretory IgA response [7].”

    From Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge (2012) · cites this paper as [7]

    The Discussion says salivary IgG in IPV recipients was low or absent, suggesting it does not protect against mucosal poliovirus infection; any protective effect of circulating IgG remains untested. It instead attributes previously reported mucosal responses after IPV to prior priming with live virus and reports mucosal IgA responses after IPV boosting in previously OPV-vaccinated people. The proposed IgG-over-IgA explanation runs contrary to that account. (LLM, conf=0.86)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

  • IPV can induce gut-homing lymphocytes and an increase in the secretion of poliovirus-specific IgA among individuals who have been previously exposed to live-attenuated or wild-type poliovirus.

    “However, IPV can induce gut-homing lymphocytes and an increase in the secretion of poliovirus-specific IgA among individuals who have been previously exposed to live-attenuated or wild-type poliovirus [6], [7].”

    From Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge (2012) · cites this paper as [7]

    The results sections report that an IPV booster induced salivary poliovirus-specific IgA in 9 of 11 previously OPV-vaccinated recipients, and that most of their poliovirus-specific IgA-producing cells expressed the mucosal-homing receptor α4β7 (pages not specified in our copy). The paper also describes serum IgA responses after IPV in people previously exposed to wild-type poliovirus, but it does not establish the claimed salivary IgA and homing-cell responses for that group. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 33

  1. 1993, Immunological Basis for Immunisation
  2. 1971, Prog. Med. Virol., 156
  3. 1969, J. Immunol., 1423
  4. 1968, N. Engl. J. Med., 893
  5. 1990, J. Infect. Dis., 1291
  6. 1985, J. Infect. Dis., 1238
  7. 1996, Immunol. Infect. Dis., 105
  8. 1966, J. Hyg., 105
  9. 1991, J. Infect. Dis., 1
  10. 1992, Bull. W. H. O., 93
  11. 1997, Clin. Diagn. Lab. Immunol., 499
  12. 1997, J. Immunol., 574
  13. 1995, Semin. Immunol., 335
  14. 1995, Scand. J. Immunol., 662
  15. 1995, Immunity, 99
  16. 1997, Clin. Diagn. Lab. Immunol., 659
  17. 1994, Clin. Diagn. Virol., 113
  18. 1995, J. Infect. Dis., 1387
  19. 1984, Prog. Med. Virol., 124
  20. 1979, Dev. Biol. Stand., 195
  21. 1994, Lancet, 665
  22. 1996, Am. J. Epidemiol., 929
  23. 1995, Clin. Exp. Immunol., 70
  24. 1995, J. Infect. Dis., 198
  25. 1995, Vaccine, 1006
  26. 1995, Respir. Crit. Care. Med., 983
  27. 1991, Zh. Mikrobiol. Epidemiol. Immunobiol., 55
  28. 1994, Science, 1395
  29. 1987, J. Clin. Microbiol., 1376
  30. 1987, J. Clin. Immunol., 319
  31. 1981, J. Immunol. Methods, 345
  32. 1986, J. Immunol. Methods, 107
  33. 1990, J. Infect. Dis., 1291

Cited by

Sorted by citations

Related

Metadata

Authors
Herremans, T. M. P. T., Reimerink, J. H. J., Buisman, A. M., Kimman, T. G., & Koopmans, M. P. G.
Affiliations
  • National Institute for Public Health and the Environment (NL)
  • Research Laboratory for Infectious Diseases, National Institute of Public Health and the Environment (RIVM) , Bilthoven ,
ORCID
Venue
The Journal of Immunology
Publisher
Oxford University Press (OUP)
Published
1999-04
Volume
162
Issue
8
Pages
5011-5018
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
DOI
10.4049/jimmunol.162.8.5011
OpenAlex
W2109715645
Cited by
149
References
29
Citations by year
2026: 4 · 2024: 4 · 2023: 7 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 5 · 2018: 6 · 2017: 7 · 2016: 9 · 2015: 8 · 2014: 5 · 2013: 11 · 2012: 6
FWCI
3.39
Type
journal article
Language
en
Open access
Licence
academic.oup.com/pages/standard-publication-reuse-rights (vor)
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • Rivm (National Institute for Public Health and the Environment) (submittedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
inactivated poliovirus vaccine, oral polio vaccine, mucosal immunity, IgA, alpha4beta7 integrin, L-selectin, B cell homing, booster vaccination, saliva IgA, poliomyelitis
MeSH terms
Adult, Antibodies, Viral, Antibody Specificity, Antibody-Producing Cells, Binding Sites, Antibody, Feces, Humans, Immunoglobulin A, Immunoglobulin G, Immunoglobulin M, Immunization, Secondary, Poliomyelitis, Poliovirus Vaccine, Inactivated, Saliva, Secretory Component, Vaccines, Inactivated, Poliovirus, Immunity, Mucosal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review